IP Library Granted Patent US 11,590,176
Granted Patent B2
US 11,590,176 · App. 16/670,695 · Granted Feb 28, 2023

Compositions of microbiota and methods related thereto

Inventors: Lee M. Kaplan (Wellesley, MA); Alice P. Liou (Charlestown, MA); Peter J. Turnbaugh (Somerville, MA); Jason L. Harris (Lebanon, OH)
Assignees: Johnson & Johnson Consumer Inc.; The General Hospital Corporation; President and Fellows of Harvard College
A61K35/74A61K9/0053A61K35/741A61K45/06C12Q1/689A61K2035/11Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,590,176
App. No.
16/670,695
Granted
Feb 28, 2023
Kind
B2
Abstract

Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.

Claims (18)

1. A method of increasing Verrucomicrobia levels in a gastrointestinal tract of a subject having decreased levels of Verrucomicrobia as compared to a normal individual, the method comprising: orally administering a composition comprising a therapeutically effective amount of bacteria comprising substantially purified Verrucomicrobia to the subject, thereby increasing the levels of Verrucomicrobia in the gastrointestinal tract of the subject so as to resemble levels of Verrucomicrobia in a gastrointestinal tract of the normal individual.

2. The method of claim 1 , wherein the normal individual is a healthy subject.

3. The method of claim 1 , wherein the normal individual is a healthy young adult.

4. The method of claim 1 , wherein the normal individual is 25 to 30 years old.

5. The method of claim 1 , wherein the normal individual is a similar age as the subject.

6. The method of claim 1 , wherein the normal individual is the same gender as the subject.

7. The method of claim 1 , wherein the normal individual is a similar weight as the subject.

8. The method of claim 1 , wherein the substantially purified Verrucomicrobia is co-administered with one or more additional probiotic strains.

9. The method of claim 1 , wherein if the bacteria comprise a mixture of bacterial strains, then at least 50% of the bacterial strains in the composition are Verrucomicrobia, Bacteroidetes, Firmicutes, or Proteobacteria.

10. The method of claim 1 , wherein the bacteria further comprise at least one of a substantially purified Bacteroidetes, a substantially purified Firmicutes, or a substantially purified Proteobacteria.

11. The method of claim 1 , wherein the bacteria further comprise substantially purified Clostridiales.

12. The method of claim 1 , wherein the composition further comprises or is co-administered with one or more prebiotics.

13. The method of claim 12 , wherein the one or more prebiotics comprises a fructooligosaccharide, a glucooligosaccharide, a xylooligosaccharide, a galactooligosaccharide, an arabinoxylan, an arabinogalactan, a galactomannan, a polydextrose, an oligofructose, an inulin, a derivative thereof, or a combination thereof.

14. The method of claim 1 , wherein the relative abundance of the Verrucomicrobia in the subject is increased by at least 5%.

15. The method of claim 1 , wherein the Verrucomicrobia is lyophilized.

16. The method of claim 1 , wherein the composition is administered in one or more doses per day.

17. The method of claim 1 , wherein the composition is administered at a dose of from about 0.001 to about 100 mg/kg body weight of the subject.

18. The method of claim 1 , wherein the composition is administered at a dose of from about 0.01 to about 50 mg/kg body weight of the subject.

Assignments (9)
CHANGE OF NAME Recorded Oct 28, 2024
From: JOHNSON & JOHNSON CONSUMER INC.
To: KENVUE BRANDS LLC
Reel/Frame 069267/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0372 →
CERTIFICATE OF CONVERSION Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0521 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2023
From: ETHICON ENDO-SURGERY, INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062341/0767 →
SECURITY INTEREST Recorded Jan 18, 2022
From: PENDULUM THERAPEUTICS, INC.
To: TRINITY CAPITAL INC.
Reel/Frame 058678/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2020
From: KAPLAN, LEE M.; LIOU, ALICE P.; TURNBAUGH, PETER J.
To: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL
Reel/Frame 054128/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2020
From: HARRIS, JASON L.
To: ETHICON ENDO-SURGERY, INC.
Reel/Frame 054128/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2020
From: TURNBAUGH, PETER J.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 054128/0957 →
QUITCLAIM ASSIGNMENT Recorded Oct 21, 2020
From: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL
To: TURNBAUGH, PETER J.
Reel/Frame 054171/0725 →